Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Galvus Review Delayed For Safety Analysis Of Primate Skin Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.

You may also be interested in...



Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.

Merck Builds On Januvia Momentum With Two Supplementary Claims

Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel